FOLH1 and prostate carcinoma: At present, PSMA-PET is routinely used for the staging of patients with newly diagnosed intermediate to high-risk prostate cancer, patients with biochemically recurrent prostate cancer, or to assess eligibility of PSMA RLT (radioligand therapy) in castration resistant prostate cancer 14,15.